All In Biotech

Drug Trial Radar · NCT00490035

Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures

A Multi-center, Double-blind, Parallel-group, Placebo Controlled, Randomized Study: Evaluation of the Efficacy and Safety of Brivaracetam in Subjects (>= 16 to 70 Years Old) With Partial Onset Seizures.

Last checked: Nov 20, 2026Latest source record: Jul 21, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 399 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

399

Actual

Start

Sep 2007

Primary completion

Feb 2009

Study completion Feb 2009

Sponsor

Lead sponsor
UCB Pharma SAUCB
Sponsor type
Industry
First posted
Jun 22, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 16 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the efficacy and safety of Brivaracetam to support the submission file in the indication of adjunctive treatment in adolescents and adults with partial onset seizures.

Conditions

  • Epilepsy

Interventions

  • PlaceboOther

    Daily oral dose of two equal intakes, morning and evening, of Placebo in a double-blinded way for the 12-week Treatment Period

  • BrivaracetamDrug

    Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 20 mg /day in a double-blinded way for the 12-week Treatment Period

  • BrivaracetamDrug

    Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 50 mg /day in a double-blinded way for the 12-week Treatment Period.

  • BrivaracetamDrug

    Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 100 mg /day in a double-blinded way for the 12-week Treatment Period.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Partial Onset Seizure (Type I) Frequency Per Week Over the 12-week Treatment PeriodTime frame: From Baseline to 12-week Treatment Period

Locations

76 sites in 12 countries. Site status is shown where the registry gives one.

  • 13

    Ghent, Belgium

  • 19

    La Louvière, Belgium

  • 12

    Liège, Belgium

  • 10

    Sankt Vith, Belgium

  • 44

    Kuopio, Finland

  • 41

    Oulu, Finland

  • 42

    Seinäjoki, Finland

  • 43

    Tampere, Finland

  • 60

    Angers, France

  • 56

    Béthune, France

  • 62

    Bron, France

  • 57

    Dijon, France

  • 53

    Lille, France

  • 52

    Montpellier, France

  • 64

    Nancy, France

  • 54

    Paris, France

  • 51

    Rennes, France

  • 61

    Roanne, France

  • 55

    Strasbourg, France

  • 76

    Bad Berka, Germany

  • 73

    Berlin, Germany

  • 79

    Bernau, Germany

  • 78

    Bielefeld, Germany

  • 74

    Freiburg im Breisgau, Germany

  • 75

    Kehl-Kork, Germany

  • 77

    Mainz, Germany

  • 70

    München, Germany

  • 72

    Radeberg, Germany

  • 71

    Ulm, Germany

  • 94

    Budapest, Hungary

  • 90

    Debrecen, Hungary

  • 92

    Pécs, Hungary

  • 256

    Bangalore, India

  • 257

    Bangalore, India

  • 253

    Hyderabad, India

  • 258

    Jaipur, India

  • 255

    Kolkata, India

  • 250

    Lucknow, India

  • 259

    Mumbai, India

  • 270

    Pune, India

Showing 40 of 76 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.